Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection

With the continued prevalence of COVID-19, repeated infection caused by SARS-CoV-2 has become common. However, studies on immune persistence post Omicron XBB reinfection are limited. We prospectively studied the durability and cross-reactivity of neutralizing antibodies (NAbs) and T cell responses a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1477721
Main Authors Zhao, Xin-Jing, Li, Xin-Lou, Zhang, Sheng, Chen, Jin-Jin, Zhao, Wei-Chao, Wu, Na-Na, Wang, Rui-Juan, Xu, Qiang, Lv, Chen-Long, Jiang, Bao-Gui, Wang, Guo-Lin, Fang, Li-Qun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 07.10.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:With the continued prevalence of COVID-19, repeated infection caused by SARS-CoV-2 has become common. However, studies on immune persistence post Omicron XBB reinfection are limited. We prospectively studied the durability and cross-reactivity of neutralizing antibodies (NAbs) and T cell responses among 20 subjects who suffered Omicron BA.5 infection with or without Omicron XBB reinfection over 6-month through the pseudovirus neutralization test and the fluorospot assay. NAbs against EG.5.1, BA.2.86, and JN.1 subvariants were decreased and undetectable at 6-month post Omicron BA.5 infection, while those elicited by Omicron XBB reinfection were significant increased and remained detectable against all detected variants within 6-month. Furthermore, in subjects with Omicron XBB reinfection, memory T cell responses could cross-recognized wild-type and Omicron spike peptides and reached peak at 3-month. Interestingly, comparable robust T cell responses were observed among non-seroconverted subjects post Omicron XBB exposure. Though the NAbs against various emerging Omicron subvariants elicited by Omicron XBB reinfection can persist for at least 6-month, the HCWs should strengthen personal protection and timely be immunized with updated vaccines upon current circulating variants or conserved T epitope.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors have contributed equally to this work and share last authorship
Cyril Planchais, Institut Pasteur, France
Reviewed by: Huang Huang, Gilead, United States
Edited by: Tara Marlene Strutt, University of Central Florida, United States
The authors have contributed equally to this work and share first authorship
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1477721